{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:58:34Z","timestamp":1790621914323,"version":"4.1.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T00:00:00Z","timestamp":1569456000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"EB Research Partnership"},{"DOI":"10.13039\/100002077","name":"Epidermolysis Bullosa Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002077","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Dermatology Foundation Medical Dermatology Career Development"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.jaad.2019.09.014","type":"journal-article","created":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T11:29:17Z","timestamp":1568806157000},"page":"1415-1421","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Phase 2 trial of a neurokinin-1 receptor antagonist for the treatment of chronic itch in patients with epidermolysis bullosa: A randomized clinical trial"],"prefix":"10.1016","volume":"82","author":[{"given":"Albert S.","family":"Chiou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Barriga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yana","family":"Dutt-Singkh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C.","family":"Solis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaron","family":"Nazaroff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Bailey-Healy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shufeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Joing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Y.","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jaad.2019.09.014_bib1","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/pde.12391","article-title":"Prevalence and characterization of pruritus in epidermolysis bullosa","volume":"32","author":"Danial","year":"2015","journal-title":"Pediatr Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2019.09.014_bib2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/bjd.12885","article-title":"Burden of itch in epidermolysis bullosa","volume":"171","author":"Snauwaert","year":"2014","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2019.09.014_bib3","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2340\/00015555-0376","article-title":"Main problems experienced by children with epidermolysis bullosa: a qualitative study with semi-structured interviews","volume":"88","author":"van Scheppingen","year":"2008","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"10.1016\/j.jaad.2019.09.014_bib4","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.det.2010.01.008","article-title":"Pain management in epidermolysis bullosa","volume":"28","author":"Goldschneider","year":"2010","journal-title":"Dermatol Clin"},{"issue":"5","key":"10.1016\/j.jaad.2019.09.014_bib5","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/pde.12486","article-title":"Evaluation of treatments for pruritus in epidermolysis bullosa","volume":"32","author":"Danial","year":"2015","journal-title":"Pediatr Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2019.09.014_bib6","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1365-2230.2008.02789.x","article-title":"A systematic review of randomized controlled trials of treatments for inherited forms of epidermolysis bullosa","volume":"34","author":"Langan","year":"2009","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2019.09.014_bib7","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/978-3-662-44605-8_14","article-title":"NK-1 antagonists and itch","volume":"226","author":"Stander","year":"2015","journal-title":"Handb Exp Pharmacol"},{"issue":"2","key":"10.1016\/j.jaad.2019.09.014_bib8","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jdermsci.2007.06.007","article-title":"Rapid changes in substance P signaling and neutral endopeptidase induced by skin-scratching stimulation in mice","volume":"48","author":"Yamaoka","year":"2007","journal-title":"J Dermatol Sci"},{"issue":"10","key":"10.1016\/j.jaad.2019.09.014_bib9","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1001\/jamadermatol.2018.2510","article-title":"Aprepitant for the treatment of pruritus in Sezary syndrome: a randomized crossover clinical trial","volume":"154","author":"Zic","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2019.09.014_bib10","first-page":"665","article-title":"Oral aprepitant in the therapy of refractory pruritus in erythrodermic cutaneous T-cell lymphoma","volume":"164","author":"Booken","year":"2011","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2019.09.014_bib11","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1001\/jamadermatol.2013.170","article-title":"The use of aprepitant in brachioradial pruritus","volume":"149","author":"Ally","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2019.09.014_bib12","doi-asserted-by":"crossref","first-page":"26","DOI":"10.2340\/00015555-2780","article-title":"Role of substance P and its receptor neurokinin 1 in chronic prurigo: a randomized, proof-of-concept, controlled trial with topical aprepitant","volume":"98","author":"Ohanyan","year":"2018","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"10.1016\/j.jaad.2019.09.014_bib13","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.jaad.2018.02.030","article-title":"Serlopitant for the treatment of chronic pruritus: results of a randomized, multicenter, placebo-controlled phase 2 clinical trial","volume":"78","author":"Yosipovitch","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2019.09.014_bib14","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nrd1130","article-title":"Clinical biomarkers in drug discovery and development","volume":"2","author":"Frank","year":"2003","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"10.1016\/j.jaad.2019.09.014_bib15","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.biopsych.2004.02.007","article-title":"Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant","volume":"55","author":"Bergstrom","year":"2004","journal-title":"Biol Psychiatry"},{"issue":"5","key":"10.1016\/j.jaad.2019.09.014_bib16","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1093\/brain\/awx069","article-title":"Recessive dystrophic epidermolysis bullosa results in painful small fibre neuropathy","volume":"140","author":"von Bischhoffshausen","year":"2017","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.jaad.2019.09.014_bib17","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.jaad.2019.01.052","article-title":"Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial","volume":"80","author":"Stander","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2019.09.014_bib18","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1365-2133.2011.10306.x","article-title":"Reduced intraepidermal nerve fibre density in lesional and nonlesional prurigo nodularis skin as a potential sign of subclinical cutaneous neuropathy","volume":"165","author":"Schuhknecht","year":"2011","journal-title":"Br J Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962219327513?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962219327513?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:55:21Z","timestamp":1759272921000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962219327513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S0190962219327513"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2019.09.014","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 2 trial of a neurokinin-1 receptor antagonist for the treatment of chronic itch in patients with epidermolysis bullosa: A randomized clinical trial","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2019.09.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}